Real TRT vs. 'TRT': what the distinction actually means clinically

What's this video probably claiming?

Derek from More Plates More Dates (@moreplates) is one of the more research-literate voices in the fitness space, and this clip, pulled from a conversation with YouTuber Will Tennyson, is almost certainly drawing a line between medically supervised testosterone replacement therapy for diagnosed hypogonadism and the kind of off-label, self-administered testosterone use that's become normalized in fitness communities. The framing of 'TRT' in quotes is doing a lot of work here. It signals that a significant portion of men calling themselves TRT patients are likely running doses far above what any endocrinologist would prescribe for hypogonadism. Derek has made this point before in long-form content: there's a clinical definition of TRT and then there's what people actually do. The conversation likely touches on how the fitness industry has blurred that line, making supraphysiologic testosterone use sound medically routine.

What does the science actually show?

Genuine TRT for hypogonadism targets serum testosterone in the 400-700 ng/dL range, roughly the mid-normal physiological window. A 2018 systematic review by Corona et al. in the Journal of Sexual Medicine found that standard injectable protocols typically use testosterone cypionate or enanthate at 50-100 mg weekly (or 100-200 mg every two weeks), producing levels that stay within or modestly above normal range. What circulates online as TRT is a different animal entirely. Doses of 200-500 mg per week are common in fitness communities, pushing total testosterone into the 1,500-3,000 ng/dL range, which is by definition anabolic steroid use, not hormone replacement. The Endocrine Society's 2018 clinical practice guidelines define hypogonadism as total testosterone consistently below 300 ng/dL on two morning measurements, with symptoms. Most men self-administering 'TRT' have never had that diagnostic workup done.

Where does the social media noise diverge from clinical reality?

The biggest distortion in fitness content is the framing of testosterone as a wellness optimization tool with a clean safety profile when used at 'reasonable' doses. Even legitimate TRT carries real risks that get minimized online. A 2023 randomized controlled trial, the TRAVERSE study (Lincoff et al., New England Journal of Medicine), found that testosterone therapy in middle-aged and older men with hypogonadism did not increase major cardiovascular events, which was reassuring, but the trial specifically used doses targeting physiological levels. That safety signal does not extend to supraphysiologic use. Polycythemia, suppression of endogenous testosterone production, testicular atrophy, and elevated hematocrit are documented even at clinical doses. At the doses fitness communities call 'TRT,' the risk profile changes substantially. Lipid dysregulation, particularly HDL suppression, becomes clinically meaningful. Social media has also almost completely erased the conversation about fertility, since exogenous testosterone suppresses spermatogenesis within weeks of starting.

What should you actually know?

If you're a man who has been told by an online clinic that your testosterone of 380 ng/dL justifies starting weekly injections, it's worth getting a second opinion from a board-certified endocrinologist or urologist. The threshold matters, and so does ruling out reversible causes like obesity, sleep apnea, and alcohol use before committing to exogenous testosterone, which will suppress your own production within weeks. A 2012 study by Coviello et al. in the Journal of Clinical Endocrinology and Metabolism showed that 200 mg of testosterone enanthate weekly suppressed sperm concentration to azoospermic levels in roughly 40% of men within six months. Recovery is not guaranteed to be fast or complete. Derek's point about the fitness industry blurring the line between TRT and steroid use is well-taken and clinically relevant. But the solution is not to dismiss TRT as illegitimate. Diagnosed hypogonadism is real, undertreated, and has significant quality-of-life consequences. The issue is precision in how we talk about it.